Alfa Wasserman deal gives Theravance $63.5m plus royalties for velusetrag
This article was originally published in Scrip
Theravance and the private Italian pharmaceutical group Alfa Wassermann have signed an exclusive development and commercialisation agreement worth up to $63.5 million plus royalties from sales for the US company's oral 5-HT4 agonist velusetrag (TD-5108) as a treatment for gastrointestinal motility disorders.
You may also be interested in...
Theravance is working out what to do next with its investigational drug for gastroparesis after it produced mixed data in a Phase IIb trial in this underserved indication.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.